This company seems to have been delisted
Reason: Acquired by Johnson & Johnson
Last recorded trade on: August 1, 2024
Source: https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-abiomed
Reason: Acquired by Johnson & Johnson
Last recorded trade on: August 1, 2024
Source: https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-abiomed
Abiomed
ABMD
₹33,002
Share price
0.00%
Change (1 day)
N/A
Change (1 year)
Categories
Abiomed is an American medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump.
Revenue for Abiomed (ABMD)
Revenue in 2022 (TTM): ₹83.43 Billion
According to Abiomed's latest financial reports the company's current revenue (TTM 
) is ₹93.03 Billion. In 2021 the company made a revenue of ₹74.66 Billion an increase over the revenue in the year 2020 that were of ₹59.45 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Abiomed from 2013 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | ₹83.43 B | 11.75% |
| 2021 | ₹74.66 B | 25.59% |
| 2020 | ₹59.45 B | -0.9% |
| 2019 | ₹59.99 B | 16.45% |
| 2018 | ₹51.51 B | 48.32% |
| 2017 | ₹34.73 B | 23.29% |
| 2016 | ₹28.17 B | 39.85% |
| 2015 | ₹20.14 B | 49.1% |
| 2014 | ₹13.51 B | 23.64% |
| 2013 | ₹10.92 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | ₹263.94 B | 183.71% | 🇺🇸 USA |
 | ₹1.450 T | 1,459.08% | 🇺🇸 USA |
 | ₹40.30 B | -56.68% | 🇺🇸 USA |